XNCR - Xencor Inc

-

$undefined

N/A

(N/A)

Xencor Inc NasdaqGM:XNCR Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Location: 465 North Halstead Street, Pasadena, CA, 91107, United States | Website: https://www.xencor.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

303.1M

Cash

469.6M

Avg Qtr Burn

-40.39M

Short % of Float

13.70%

Insider Ownership

1.22%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Update

XmAb942 Details
Inflammatory bowel disease

Phase 2b

Initiation

Plamotamab (CD20xCD3) Details
Autoimmune disease, Rheumatoid arthritis

Phase 1/2

Initiation

XmAb541 (CLDN6 x CD3) Details
Ovarian cancer, Solid tumor/s

Phase 1

Data readout

Plamotamab (CD20xCD3) Details
Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, B-cell malignancies

Phase 1

Data readout

XmAb808 + pembrolizumab Details
Solid tumor/s, Prostate cancer

Phase 1

Data readout

XmAb819 (ENPP3 x CD3) Details
Renal cell carcinoma

Phase 1

Data readout

XmAb662 (IL12-Fc) Details
Cancer, Solid tumor/s

Phase 1

Update

XmAb657 Details
Autoimmune disease

Phase 1

Initiation

XmAb564 (IL-2-Fc) Details
Autoimmune disease, Psoriasis, Atopic dermatitis

Phase 1a

Update

Tidutamab (SSTR2xCD3) Details
Cancer, Neuroendocrine tumor, Gastrointestinal stromal tumors

Failed

Discontinued

Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details
Cancer, Non-small cell lung carcinoma

Failed

Discontinued

Vibecotamab (CD123xCD3) Details
Acute myeloid leukemia

Failed

Discontinued

Vudalimab (XmAb®717) (PD-1 x CTLA-4) Details
Renal cell carcinoma, Cancer, Prostate cancer

Failed

Discontinued